Description
ML141 is a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase. The EC50 for Cdc42 wild type and Cdc42Q61L mutant were 2.1 and 2.6 μM respectively. It has excellent selectivity for Cdc42 with no inhibition toward Rho and Rac in the same GTPase family, including Rac1, Rab2 and Rab7. In cellular assays ML141 inhibited Cdc42-related filopodia formation and cell migration.
Product information
CAS Number: 71203-35-5
Molecular Weight: 407.49
Formula: C22H21N3O3S
Synonym:
CID2950007
Chemical Name: 4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide
Smiles: COC1C=CC(=CC=1)C1CC(=NN1C1C=CC(=CC=1)S(N)(=O)=O)C1C=CC=CC=1
InChiKey: QBNZBMVRFYREHK-UHFFFAOYSA-N
InChi: InChI=1S/C22H21N3O3S/c1-28-19-11-7-17(8-12-19)22-15-21(16-5-3-2-4-6-16)24-25(22)18-9-13-20(14-10-18)29(23,26)27/h2-14,22H,15H2,1H3,(H2,23,26,27)
Technical Data
Appearance: Solid Power.
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO up to 100 mM
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined.
HS Tariff Code: 382200
How to use
In Vitro:
ML141 was used at 10 µM final concentration in various in vitro assays.
References:
- Chen HY, et al. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. (2013) EMBO Mol Med. 5(5):723-36.
- Surviladze Z, et al. A Potent and Selective Inhibitor of Cdc42 GTPase. (2010) Probe Reports from the NIH Molecular Libraries Program.
Products are for research use only. Not for human use.
Documents
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.